"Teaching old drugs to kill new bugs": Structure-based discovery of anti-SARS drugs

Biochemical and Biophysical Research Communications

Volumn 321, Issue 2, 2004, Pages 370-378

  Rajnarayanan, Rajendram V ^a   Dakshanamurthy, Sivanesan ^a   Pattabiraman, Nagarajan ^a,b  

^a GEORGETOWN UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

3CL protease; Cysteine protease; Protease inhibitors; Severe acute respiratory syndrome; Virtual screening

Indexed keywords

4,7 DIBENZYL 2,3,4,5,6,7 HEXAHYDRO 5,6 DIHYDROXY 1,3 BIS[4 (HYDROXYMETHYL)BENZYL] 2H 1,3 DIAZEPIN 2 ONE; A 80987; ALUVIRAN; AMPRENAVIR; ANTIVIRUS AGENT; BMS 186318; CYSTEINE PROTEINASE; CYSTEINE PROTEINASE INHIBITOR; INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; RUPINTRIVIR; SAQUINAVIR; 3C LIKE PROTEASE, SARS CORONAVIRUS; 3C-LIKE PROTEASE, SARS CORONAVIRUS; LIGAND; UREA; VIRUS PROTEIN;

ARTICLE; CRYSTAL STRUCTURE; DATA BASE; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; HUMAN; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; SEVERE ACUTE RESPIRATORY SYNDROME; STRUCTURE ACTIVITY RELATION; VIRTUAL REALITY; BINDING SITE; BIOLOGY; CHEMICAL STRUCTURE; CHEMISTRY; CYCLIZATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; METABOLISM; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; SARS CORONAVIRUS; X RAY CRYSTALLOGRAPHY;

ANTIVIRAL AGENTS; BINDING SITES; COMPUTATIONAL BIOLOGY; CRYSTALLOGRAPHY, X-RAY; CYCLIZATION; CYSTEINE ENDOPEPTIDASES; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; ENDOPEPTIDASES; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN STRUCTURE, TERTIARY; SARS VIRUS; STRUCTURE-ACTIVITY RELATIONSHIP; UREA; VIRAL PROTEINS;

EID: 3242795819     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2004.06.155     Document Type: Article

References (30)

1. J.S. Peiris Severe acute respiratory syndrome (SARS) J. Clin. Virol. 28 2003 245 247
2. P. Basu Biotech firms jump on SARS bandwagon Nat. Biotechnol. 21 2003 720
3. A. Abbott US Army joins hunt for SARS drug Nature 423 2003 103
4. M.A. Marra, S.J. Jones, C.R. Astell, R.A. Holt, A. Brooks-Wilson, Y.S. Butterfield, J. Khattra, J.K. Asano, S.A. Barber, S.Y. Chan, A. Cloutier, S.M. Coughlin, D. Freeman, N. Girn, O.L. Griffith, S.R. Leach, M. Mayo, H. McDonald, S.B. Montgomery, P.K. Pandoh, A.S. Petrescu, A.G. Robertson, J.E. Schein, A. Siddiqui, D.E. Smailus, J.M. Stott, G.S. Yang, F. Plummer, A. Andonov, H. Artsob, N. Bastien, K. Bernard, T.F. Booth, D. Bowness, M. Czub, M. Drebot, L. Fernando, R. Flick, M. Garbutt, M. Gray, A. Grolla, S. Jones, H. Feldmann, A. Meyers, A. Kabani, Y. Li, S. Normand, U. Stroher, G.A. Tipples, S. Tyler, R. Vogrig, D. Ward, B. Watson, R.C. Brunham, M. Krajden, M. Petric, D.M. Skowronski, C. Upton and R.L. Roper The genome sequence of the SARS-associated coronavirus Science 300 2003 1399 1404
5. K. Anand, J. Ziebuhr, P. Wadhwani, J.R. Mesters and R. Hilgenfeld Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs Science 300 2003 1763 1767
6. K.C. Chou, D.Q. Wei and W.Z. Zhong Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS Biochem. Biophys. Res. Commun. 308 2003 148 151
7. B. Xiong, C.S. Gui, X.Y. Xu, C. Luo, J. Chen, H.B. Luo, L.L. Chen, G.W. Li, T. Sun, C.Y. Yu, L.D. Yue, W.H. Duan, J.K. Shen, L. Qin, T.L. Shi, Y.X. Li, K.X. Chen, X.M. Luo, X. Shen, J.H. Shen and H.L. Jiang A 3D model of SARS_CoV 3CL proteinase and its inhibitors design by virtual screening Acta Pharmacol. Sin. 24 2003 497 504
8. E. Jenwitheesuk and R. Samudrala Identifying inhibitors of the SARS coronavirus proteinase Bioorg. Med. Chem. Lett 13 2003 3989 3992
9. J.H. Toney, S. Navas-Martin, S.R. Weiss and A. Koeller Sabadinine: a potential non-peptide anti-severe acute-respiratory-syndrome agent identified using structure-aided design J. Med. Chem. 47 2004 1079 1080
10. J.B. Bonanno, R. Fowler, S. Gupta, J. Hendle, D. Lorimer, R. Romero, M. Sauder, C.L. Wei, E.T. Liu, S.K. Burley, T. Harris, X-Ray Crystal Structure of the Sars Coronavirus Main Protease. Available from: 〈http://www.rcsb.org/ pdb/cgi/explore.cgi?pdbId=1q2w〉 (2003)
11. H. Yang, M. Yang, Y. Ding, Y. Liu, Z. Lou, Z. Zhou, L. Sun, L. Mo, S. Ye, H. Pang, G.F. Gao, K. Anand, M. Bartlam, R. Hilgenfeld and Z. Rao The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor Proc. Natl. Acad. Sci. USA 100 2003 13190 13195
12. U. Bacha, J. Barrila, A. Velazquez-Campoy, S.A. Leavitt and E. Freire Identification of novel inhibitors of the SARS coronavirus main protease 3CL(pro) Biochemistry 43 2004 4906 4912
13. B. Vastag Old drugs for a new bug: influenza, HIV drugs enlisted to fight SARS JAMA 290 2003 1695 1696
14. G. Koren, S. King, S. Knowles and E. Phillips Ribavirin in the treatment of SARS: A new trick for an old drug? CMAJ 168 2003 1289 1292
15. X.W. Zhang and Y.L. Yap Old drugs as lead compounds for a new disease? Binding analysis of SARS coronavirus main proteinase with HIV, psychotic and parasite drugs Bioorg. Med. Chem. 12 2004 2517 2521
16. G. Jones, P. Willett and R.C. Glen Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation J. Mol. Biol. 245 1995 43 53
17. E.C. Meng, B.K. Shoichet and I.D. Kuntz Automated docking with grid-based energy evaluation J. Comput. Chem. 13 1992 505 524
18. M.D. Eldridge, C.W. Murray, T.R. Auton, G.V. Paolini and R.P. Mee Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes J. Comput. Aided Mol. Des. 11 1997 425 445
19. I. Muegge and Y.C. Martin A general and fast scoring function for proteinâ€"ligand interactions: a simplified potential approach J. Med. Chem. 42 1999 791 804
20. M. Rarey, B. Kramer, T. Lengauer and G. Klebe A fast flexible docking method using an incremental construction algorithm J. Mol. Biol. 261 1996 470 489
21. C.C. Huang, G.S. Couch, E.F. Pettersen and T.E. Ferrin Chimera: an extensible molecular modeling application constructed using standard components Pac. Symp. Biocomput. 1 1996 724
22. N. Pattabiraman Occluded molecular surface analysis of ligand-macromolecule contacts: application to HIV-1 proteaseâ€" inhibitor complexes J. Med. Chem. 42 1999 3821 3834
23. N. Pattabiraman, K.B. Ward and P.J. Fleming Occluded molecular surface: analysis of protein packing J. Mol. Recognit. 8 1995 334 344
24. G. Witherell AG-7088 Pfizer Curr. Opin. Investig. Drugs 1 2000 297 302
25. D.A. Matthews, P.S. Dragovich, S.E. Webber, S.A. Fuhrman, A.K. Patick, L.S. Zalman, T.F. Hendrickson, R.A. Love, T.J. Prins, J.T. Marakovits, R. Zhou, J. Tikhe, C.E. Ford, J.W. Meador, R.A. Ferre, E.L. Brown, S.L. Binford, M.A. Brothers, D.M. DeLisle and S.T. Worland Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes Proc. Natl. Acad. Sci. USA 96 1999 11000 11007
26. P.S. Dragovich, T.J. Prins, R. Zhou, S.E. Webber, J.T. Marakovits, S.A. Fuhrman, A.K. Patick, D.A. Matthews, C.A. Lee, C.E. Ford, B.J. Burke, P.A. Rejto, T.F. Hendrickson, T. Tuntland, E.L. Brown, J.W. Meador 3rd, R.A. Ferre, J.E. Harr, M.B. Kosa and S.T. Worland Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as l-glutamine replacements J. Med. Chem. 42 1999 1213 1224
27. N.A. Thornberry, T.A. Rano, E.P. Peterson, D.M. Rasper, T. Timkey, M. Garcia-Calvo, V.M. Houtzager, P.A. Nordstrom, S. Roy, J.P. Vaillancourt, K.T. Chapman and D.W. Nicholson A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis J. Biol. Chem. 272 1997 17907 17911
28. K. Fan, P. Wei, Q. Feng, S. Chen, C. Huang, L. Ma, B. Lai, J. Pei, Y. Liu, J. Chen and L. Lai Biosynthesis, purification, and substrate specificity of severe acute respiratory syndrome coronavirus 3C-like proteinase J. Biol. Chem. 279 2004 1637 1642
29. A. Wiley, G. Deslongchamps, Homology Model of SARS-CoV Mpro Protease. Available from: 〈http://biocomp.chem.unb.ca:8080/GD/SARS/〉 (2003)
30. H.M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T.N. Bhat, H. Weissig, I.N. Shindyalov and P.E. Bourne The Protein Data Bank. Nucleic Acids Res. 28 2000 235 242